Want to see NIKI full AI Analyst Report?
Top Page
Niki BioSolutions Inc
(NASDAQ:NIKI)
Select Model
Select Model
Rating:44Neutral
Price Target:
$6.00
▼(-24.05% Downside)
Action:Reiterated
Date:09/06/26
The score is driven primarily by weak financial performance (near-zero revenue, ongoing losses, and continued cash burn) and bearish technicals (below key moving averages with negative MACD). These pressures are only partially offset by a relatively steadier balance sheet and positive corporate developments (Nasdaq compliance regained and leadership changes tied to merger/fundraising).
Positive Factors
Supportive balance sheet
A relatively resilient balance sheet gives this development-stage biotech a buffer while it advances candidates and funds operations. Improved leverage and sizable equity may preserve financial flexibility, although that support depends on containing continued losses.
Negative Factors
Commercial revenue has collapsed to near zero
The absence of meaningful recent revenue shows that the company has not yet established commercial scale or a recurring operating revenue base. This leaves value dependent on successful clinical development, partnering, or future commercialization rather than current product demand.
Read all positive and negative factors
Positive Factors
Negative Factors
Supportive balance sheet
A relatively resilient balance sheet gives this development-stage biotech a buffer while it advances candidates and funds operations. Improved leverage and sizable equity may preserve financial flexibility, although that support depends on containing continued losses.
Read all positive factors
Niki BioSolutions Inc (NIKI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.05M
Dividend YieldN/A
Average Volume (3M)175.15K
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.20
Shares Outstanding634,682
10 Day Avg. Volume471,287
30 Day Avg. Volume175,151
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-4.24
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)31
Revenue Forecast (FY)$106.80M
Niki BioSolutions Inc Business Overview & Revenue Model
Company Description
Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans ...
How the Company Makes Money
Aptorum’s primary business model is to create value by advancing drug candidates through development and, where possible, monetizing those assets via partnering transactions and eventual commercialization. Specific, company-level details on recurr...
Niki BioSolutions Inc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 431.38K | 1.30M | 1.54M |
| Gross Profit | 0.00 | -255.00K | 10.57K | 80.06K | 81.85K |
| EBITDA | -1.82M | -3.76M | -9.48M | -10.32M | -25.83M |
| Net Income | -1.36M | -4.27M | -2.83M | -9.80M | -25.05M |
Balance Sheet | |||||
| Total Assets | 18.69M | 16.13M | 20.64M | 20.87M | 21.91M |
| Cash, Cash Equivalents and Short-Term Investments | 3.45M | 874.24K | 2.01M | 1.99M | 8.50M |
| Total Debt | 3.44M | 3.35M | 3.28M | 6.85M | 217.17K |
| Total Liabilities | 4.90M | 4.35M | 5.26M | 13.03M | 4.40M |
| Stockholders Equity | 23.16M | 21.13M | 24.85M | 15.71M | 23.61M |
Cash Flow | |||||
| Free Cash Flow | -1.84M | -1.19M | -7.73M | -12.51M | -14.79M |
| Operating Cash Flow | -1.84M | -1.19M | -7.72M | -12.32M | -14.65M |
| Investing Cash Flow | 0.00 | 58.62K | 624.77K | 2.44M | 16.51M |
| Financing Cash Flow | 4.42M | 0.00 | 4.09M | 6.63M | 2.78M |
Niki BioSolutions Inc Technical Analysis
Negative
7.90
Price Trends
8.22
Negative
8.57
Negative
9.34
Negative
Market Momentum
-0.60
Positive
30.08
Neutral
3.18
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NIKI, the sentiment is Negative. The current price of 7.9 is above the 20-day moving average (MA) of 7.83, below the 50-day MA of 8.22, and below the 200-day MA of 9.34, indicating a bearish trend. The MACD of -0.60 indicates Positive momentum. The RSI at 30.08 is Neutral, neither overbought nor oversold. The STOCH value of 3.18 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NIKI.
Niki BioSolutions Inc Risk Analysis
Niki BioSolutions Inc disclosed 73 risk factors in its most recent earnings report. Niki BioSolutions Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Niki BioSolutions Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $77.84M | -0.26 | -47.85% | ― | ― | 52.36% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $12.01M | -0.06 | 204.18% | ― | ― | 35.03% | |
44 Neutral | $5.05M | -0.33 | -5.94% | ― | ― | ― | |
38 Underperform | $8.87M | -0.35 | -314.89% | ― | ― | 71.67% |
* Healthcare Sector Average
NIKI
Niki BioSolutions Inc
6.20
-11.80
-65.56%
IMNN
Imunon
1.58
-4.24
-72.85%
DWTX
Dogwood Therapeutics
2.29
-2.54
-52.59%
AEON
AEON Biopharma
0.24
-0.51
-68.00%
OSRH
OSR Holdings
0.23
-0.38
-62.93%
Niki BioSolutions Inc Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A Transactions
Niki BioSolutions appoints new CEO and COO leadership
Positive
Sep 4, 2026
In connection with a previously announced merger, Niki BioSolutions Inc. appointed Ian Huen as chief executive officer and Alidad Mireskandari as president and chief operating officer, with their agreements entered on September 1, 2026 and effecti...
Delistings and Listing ChangesRegulatory Filings and Compliance
Niki BioSolutions Regains Nasdaq Bid-Price Compliance Status
Positive
Aug 7, 2026
On March 5, 2026, Niki BioSolutions received a notice from Nasdaq that its common stock had closed below the $1.00 minimum bid price for 30 consecutive business days, triggering a compliance period through September 1, 2026. On August 4, 2026, Nas...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.